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Abstract
Background: Many studies have suggested a relationship between metabolic abnormalities and impaired fetal
growth with the development of non-transmissible chronic diseases in the adulthood. Moreover, it has been
proposed that maternal factors such as endothelial function and oxidative stress are key mechanisms of both fetal
metabolic alterations and subsequent development of non-transmissible chronic diseases. The objective of this
project is to evaluate the effect of micronutrient supplementation and regular aerobic exercise on endothelium-
dependent vasodilation maternal and stress oxidative of the newborn.
Methods and design: 320 pregnant women attending to usual prenatal care in Cali, Colombia will be included in
a factorial randomized controlled trial. Women will be assigned to the following intervention groups: 1. Control
group: usual prenatal care (PC) and placebo (maltodextrine). 2. Exercise group: PC, placebo and aerobic physical
exercise. 3. Micronutrients group: PC and a micronutrients capsule consisting of zinc (30 mg), selenium (70 μg),
vitamin A (400 μg), alphatocopherol (30 mg), vitamin C (200 mg), and niacin (100 mg). 4. Combined interventions
Group: PC, supplementation of micronutrients, and aerobic physical exercise. Anthropometric measures will be
taken at the start and at the end of the interventions.
Discussion: Since in previous studies has been showed that the maternal endothelial function and oxidative stress
are related to oxidative stress of the newborn, this study proposes that complementation with micronutrients
during pregnancy and/or regular physical exercise can be an early and innovative alternative to strengthen the
prevention of chronic diseases in the population.
Trial registration: NCT00872365.
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In the last decades, it has been suggested that maternal
factors such as endothelial function and oxidative stress
are key mechanisms in fetal metabolic alterations and
the subsequent development of non-transmissible
chronic diseases [NTCD] in the adulthood [1].
In addition to the effect of these factors, other external
factors such as lifestyle, physical activity, diet, and tobacco
consumption could be involved in the development and
progress of non-transmissible chronic diseases [1] How-
ever, the interaction between the maternal and the exter-
nal factors during pregnancy that could be involved in the
development and progression of NTCD remains unclear.
Therefore, it is necessary to establish if maternal and
external factors have influence on the placental function
and on the neonatal metabolic alterations or both.
During pregnancy, several factors could affect the orga-
nization of fetal systems and sub-systems [2-4]. It has
been proposed that interventions such as the supplemen-
tation with micronutrients and the practice of physical
exercise could decrease the incidence or progression of
NTCD, probably because both interventions have been
reported to increase the synthesis of nitric oxide, a very
important factor for the function of the vascular endothe-
lium and for reduction of the oxidative stress [3-5].
This postulate has been primarily based on evidence
that ingestion of some micronutrients (e.g, vitamin and
minerals, among others, etc.) [6] and regular physical
activity (at least of 12 weeks) [7], decreases oxidative
stress [8] and restore endothelial function [9] in non-
pregnant women [10]. However, the effect of these
interventions have not been studied during pregnancy,
although both are safe and economically feasible [11].
Furthermore, most studies have focused on measuring
the effects on anthropometric measurements of neo-
nate (i.e., weight, height, among others) [12-14] despite
the possible independent relationship between the
endogenous factors and anthropometric characteristics
[15-17].
The objective of this study is to determine the effect
of the micronutrients supplementation and regular aero-
bic exercise during pregnancy on maternal endothelial
function and neonatal oxidative stress. Furthermore, the
effect of both interventions on the anthropometric para-
meters of the newborn will be evaluated. We expect
that the results of this study will provide valuable infor-
mation to design efficient public health policies during
pregnancy aimed to prevent NTCD.
Hypothesis
Supplementation with micronutrients or regular aerobic
exercise improves endothelial function in the mother
and reduces oxidative stress in newborn.
Methods/Design
Study Design
This is a single blind, randomized controlled 2 × 2 fac-
torial trial designed to evaluate the effectiveness of
micronutrients supplementation and regular aerobic
exercise during pregnancy. This design provides the
advantage of assessing the independent and cumulative
effects of the interventions in nulliparous pregnant
women.
Interventions
All women included in the study will receive usual pre-
natal care according to WHO guidelines. The following
intervention groups will be compared:
1. Control Group
This group will receive the usual prenatal care according
to both WHO and Colombian guidelines and placebo
(maltodextrine). In Colombia, pregnant women receive
ferrous sulphate, calcium, and folic acid during prenatal
care. In addition, they receive counselling about breast-
feeding, key signs and symptoms, diet and screening for
pregnancy diseases. The Colombian guidelines do not
include physical exercise prescription during pregnancy
neither counselling from a physical therapist [18].
2. Exercise Group
Regular aerobic exercise: walking (10 minutes), aerobic
exercise (30 minutes), stretching (10 minutes), and
relaxation exercises (10 minutes) during a three-month
period. Exercise will be performed during 3 sessions per
week. A physical therapist and a physical educator will
supervise all sessions. The exercise-program is according
to the American College of Obstetrics and Gynecology
(ACOG) [18] and the American College of Sports Medi-
cine (ACSM) exercise prescription [19]. Aerobic activ-
ities will be performed at moderate intensity (60-70% of
maximal heart rate) measured by the 6-20 Borg’sr a t i n g
scale (PER). Each session will start with a 5 min warm
up, followed by 30 min of aerobic activity, including a
5 min cool down. Subsequently, a 15 min strength train-
ing for upper limbs, lower limbs, and deep abdominal
muscle stabilization. The last 5 min consist of stretching
and relaxation exercises. (Table 1)
3. Micronutrients Supplemental Group
This group will receive supplementation of zinc (30 mg),
selenium (70 μg), vitamin A (400 μg), alphatocopherol
(30 mg), vitamin C (200 mg), and niacin (100 mg).
4. Combined interventions Group
This group will receive both the supplementation with
micronutrients and physical exercise as described above.
Sample size
Measurement of endothelial function (FMD), validated
in several population studies was selected as the critical
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conservatively calculated to detect all six pairwise differ-
ence between treatment groups with a Bonferroni
adjustment for an overall 0.05 type I error (0.05/6 =
0.0083) [20]. A sample size of 320 subjects or 80 per
treatment group was estimated. The sample size was
calculated assuming a specific difference between the
groups of 4.3% in the FMD after 3 months of treatment
with 11 of maximum standard deviation. It was accepted
a type I error of 0.05, a power of 80%, and it was
adjusted by 20% [20].
Eligible women for the present study and those inter-
ested in participating will be invited to a pre-test that
includes an interview (Visit A) and further assessments
that will be performed at the Red de Salud Ladera
(Hospital Cañaveralejo, Centro de Salud Meléndez, Cen-
tro de Salud Siloé, Hospital Universitario del Valle) and
at the Laboratory of Biochemistry of the Universidad of
Valle, Cali-Colombia. The first visit will take place
between weeks 12 and 20 (Visit B), the second at week
32 and 36 (Visit C) and the last one, after delivery
(Visit D).
Settings
The trial will be conducted in Cali, the third largest city
of Colombia. The study will be carried out in six public
health care institutions, which offer prenatal care in the
first level of complexity to people living in the lowest
socioeconomic stratum of the population. These institu-
tions are located in the southwest area from Cali (Red
de Salud Ladera) and provide services mainly for the
government-subsidized population in the Colombian
healthcare system. The Ethics Committees of Universi-
dad del Valle and Red de Salud Ladera (Resolution-017/
08-UV and SCAH/0408-A/08) approved the trial. All
participants will provide written informed consent
before entering the study.
Outcome variables
1. The primary outcome is the change of endothelium-
dependent brachial artery flow-mediated dilatation
(FMD) after three months of regular aerobic exercise.
[Time Frame: Baseline and 32 to 36 weeks of gestation].
2. The secondary outcome is the concentration of F2-
isoprostanes in umbilical cord blood of newborn [Time
Frame: Delivery].
Analytic plan
A l lp r e g n a n tw o m e ns t u d i e dw i l lb ea n a l y z e da c c o r d i n g
to original group allocation and all changes in outcome
variables will be attributed to the assigned treatment.
An exploratory analysis will be performed to determine
frequency, range, variability, and distribution type for
each variable in order to use the most appropriated sta-
tistical test when comparisons will be necessary. Subse-
quently, a descriptive analysis of the socio-demographic
characteristics, gestational variables, and baseline mea-
sures (x0) will be performed for each comparison group.
These analyses permit to assess the primary analysis of
the data and will be undertaken using the principle of
intention-to-treat (ITT). The ITT analysis for this study
will include all participants, including those who are not
fully compliant and those with missing outcome data.
While we plan to implement procedures to minimize
loss to follow-up and patient withdrawal, we expect to
observe some attrition. We plan to employ multiple
imputations to handle missing data in the analysis. Mul-
tiple imputations, compared to other case deletion stra-
tegies, can provide valid inferences with less restrictive
assumptions surrounding the mechanism for missing
data [21-23].
Due to that this is an experimental design with two
measures of the maternal outcome variable, the first at
baseline x0 (t0 = 16-20 gestational weeks) and the second
after interventions x1 (t1 = 32-36 gestational weeks) in
four study groups, a comparative analysis between these
measures to establish differences will be executed. In
order to perform these comparisons one way ANOVA
[24] or Kruskal-Wallis [25] tests will be applied, if appro-
priated. Subsequently, a multivariate analysis will be car-
ried out and the autocorrelation between repeated
measures will be taking in to account. We will use longi-
tudinal analysis methods such as GEE in order to control
the differences among measures at baseline and to incor-
porate incomplete observations into this analysis [26].
In order to evaluate the effects of maternal regular
physical exercise and micronutrients supplementation
on newborn’s oxidative stress (concentration of F2-
Isoprostanes in umbilical cord blood), a compara-
tive analysis will be executed to establish if the effects
are different among study groups using analysis of cov-
ariance (ANCOVA), a form of general linear model
[ 2 6 ] .W ew i l li n c l u d et h eb a s e l i n em e a s u r ea sac o v a r i -
ate in the model and pre-specified potential confound-
ing factors: maternal age, previous physical exercise
level, tobacco or alcohol consumption, differences in
diet report and pregnancy complications such as
Table 1 Pregnancy 2 X 2 Factorial Design
Regular Physical Exercise
- +
Micronutrients
- Usual Prenatal Care +
Placebo
Usual Prenatal Care +
Regular physical exercise
+ Usual Prenatal Care +
Micronutrients
Supplementation
Usual Prenatal Care +
Regular physical exercise +
Micronutrients
Supplementation
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regardless of whether baseline imbalance exists. This
approach has been chosen because confounder selec-
tion strategies that are based on collected data can
result in models with poor statistical properties [26].
This will adjust appropriately for any baseline imbal-
ance and will provide the most powerful analysis.
Adjusted estimates of intervention effect from this
model will be reported as the primary analysis in the
trial publication.
Finally, we will investigate if there is an interaction
between the two interventions for the primary outcome
at 32 gestational weeks (regular physical exercise) or
until the birth (micronutrients supplementation). For
these analyses we will include appropriate interaction
terms in the models [26]. The trial is not powered to
detect these interactions and is likely to have poor preci-
sion for the interaction terms. We plan to report regres-
sion coefficients for the interaction terms and their 95%
confidence intervals.
Eligibility
Pregnant nulliparous women (n = 320) in a range of age
between 16 to 30 years will be invited to participate in
this randomized clinical trial. These women will not any
indications of additional specialized care.
Exclusion criteria
Pregnancy with history of high blood pressure, chronic
medical illnesses (cancer, renal, endocrinologic, psychia-
tric, neurologic, infectious and cardiovascular diseases),
persistent bleeding after week 12 of gestation, poorly
controlled thyroid disease, placenta praevia, incompetent
cervix, polyhydramnios, oligohydramnios, history of mis-
carriage in the last twelve months, diseases that could
interfere with participation in the study (following
recommendations from ACSM 2000, ACOG 2002)
[18,19] or any medical condition are excluded from the
trial.
Inclusion Criteria
Nulliparous women not involved in a structured exercise
program during pregnancy will be chosen, having a live
fetus at the routine ultrasound scan, and a normal preg-
nancy, with gestational age 16 to 20 weeks. Written
informed consent will be obtained from each woman
prior to the inclusion in the study.
Blinding and Randomization methods
The randomization procedure into the two study arms
was performed by the Fundación FES Social, Division de
Salud, Cali-Colombia (Biometry and Epidemiology
Department). The biometricians compiled an allocation
list which was the basis for the pharmacists to prepare
sequentially numbered envelopes containing two boxes
of study medication for trial use. The boxes contained a
zinc (30 mg), selenium (70 μg), vitamin A (400 μg),
alphatocopherol (30 mg), vitamin C (200 mg), and nia-
cin (100 mg) or an equivalent placebo capsule (malto-
dextrine). After inclusion into the trial, the study
researcher assigned the content of the lowest numbered
envelope to the participant. The principal investigator
and coordinator the allocation sequence, and randomi-
zation is performed through a secure website which
ensures allocation concealment. All participants and
study personnel (including investigators, research coor-
dinators, data analysts) will be blinded to treatment allo-
cation throughout the trial (Table 1). Access to the
allocation code will be restricted to one study statistician
who will not perform the final study analyses. Also,
neither the participant nor the study researcher knew
about the content of the boxes, the capsule was not dis-
tinguishable. Since no specific qualifications or experi-
ence are required for the research assistants, training
will be provided prior to the initiation of the trial about
protocol and measurement procedures and methods
used to maintain the blindness. These procedures are
also detailed in the study operations manual. Moreover,
the importance of maintaining the blinding and alloca-
tion concealment will be reinforced by regularly sched-
uled conference calls at the sites and daily meetings
with the field investigators, Figure 1.
Procedures
Enrolment
A 15-month period is expected for enrolment of
study participants. Screening of participants will con-
sist in the evaluation of inclusion and exclusion cri-
teria, explanation of the study protocol, and the
assessment of the willingness to participate in the
study, (Figure 1). Eligible subjects will be scheduled
to the following visits:
- Visit A: consists of a structured validated interview
(socio-demographic data, habits, and medical record)
and a detailed physical examination by a nurse and a
gynecologist. Prenatal care visits will be continued in
the primary care center assigned to the healthcare insur-
ance plan of each woman.
Baseline assessments and active follow-up
- Visit B: measurements of blood pressure, anthropo-
metric parameters, FMD, functional capacity (VO2Max),
and electrocardiogram. During this visit, the participants
will be randomized to one of the four intervention
groups. For this purpose, a randomization system using
maximum blocks of 10 will be used.
- Visit C: within 32 and 36 week period of gestation,
measurements described above are repeated.
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recorded at postpartum: pregnancy duration, blood pres-
sure, characteristics of delivery (route and duration of
delivery, and postpartum haemorrhage), newborn out-
comes (gestational age at birth, Apgar score, weight,
height, head circumference, and abdominal circumfer-
ence). With these measures, the following variables will
be calculated: weight/height
3, head circumference/birth
weight, and weight/height [27]. In umbilical cord blood,
measurements of the following outcomes will be
obtained: oxidative stress biomarker (F2-isoprostanes).
In addition, the number of prenatal controls and infor-
mation regarding pregnancy complications will be
registered.
Passive follow-up
All the women included in the study will undergo a pas-
sive follow-up interview at day 30
th after delivery. This
follow-up will be performed via phone or direct house
visit in those cases where no phone number is available
for contact.
Physical measurements
Anthropometric parameters will be determined in each
participant at enrolment and before delivery. All mea-
surements will be performed in fasting patients, wearing
light clothes and without shoes, using standardized for-
mats and methods. In addition, these parameters will be
taken in duplicate by the same examiner on each
woman.
Weight will be measured with the patient in standing
position and then registered with 200 g approximation.
The weight scale will be calibrated to 0 before each
measurement.
Height will be measured using a metric tape with the
patient in standing and vertical position leaned against
the wall in Frankfort’s position, and the value marked
by a ruler placed horizontally on the head of the patient.
Heart rate or number of beats per minute will be
measured in the radial artery.
Blood pressure will be taken twice (with a 5 min per-
iod between the measurements) using a mercury sphyn-
gomanometer on the right arm, with the patient
comfortably seated, after a 5 min rest. Systolic blood
pressure (SBP) will be determined by the first audible
sound (Korotkoff phase 1). Diastolic blood pressure
( D B P )w i l lb er e g i s t e r e dw h e nt h es o u n dd i s a p p e a r s
(Korotkoff phase 5) [28]. The patient should not have
smoked 30 min prior to the blood pressure measure-
ment. The pneumatic arm cuff must cover 2/3 of the
upper arm’s length; its inferior border must be 2-3 cm
over the antecubital space; the cuff will be slowly
deflated. The mean blood pressure (MBP), will be calcu-
lated using the following formula [SBP+(2 × DBP)]/3.
Body composition that includes indirect fat mass per-
centage (FM; kg) and fat-free soft tissue mass (FFT; kg)
will be measured at baseline and follow-up visits using
indirect formulas [29].
Body Mass Index (BMI) will be estimated using the
weight in kg divided by the second power of the height
expressed in meters.
Functional Capacity (VO2max) will be determined in
order to find the pregnancy-specific anaerobic threshold
(AT). All women will perform an incremental sub-maxim
exercise test of the ramp type. This test will be carried out
on a mechanically braked cycloergometer (Monarck 820K)
at a bench height to facilitate the most effective pedalling.
Participants will be instructed to perform the test for as
long as possible to ensure a true maximal attempt. Stan-
dard ACSM [19] test termination criteria will be monitored
and followed throughout each test. After a 3-min warm-up
at 20 watts, the work rate will increase every minute by
Figure 1 Study design.
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up at 60 rpm. Blood pressure, heart rate and perception of
exhaustion will be monitored every minute. The incremen-
tal workload will be discontinued when either heart rate of
160 beat per min or the maximum level of exhaustion on
Borg’s scale are reached; another 3-min workload will be
performed at 10 watts followed for cooling down before
completion of the exercise test.
Measurement of flow-mediated dilatation of the brachial
artery
Endothelium-dependent vasodilatation will be measured
with the technique introduced by Silva et al. [30], using
the guidelines reported by Corretti et al. [31] The dia-
meter of the brachial artery will be assessed using a
high-resolution ultrasound device (Siemens SG-60,
USA), equipped with a 7.5 MHz linear array transducer
and an integrated electrocardiography package. The
ultrasound procedures will be performed with the sub-
ject resting quietly in supine position for at least
10 min. All measurements will be taken at the end of
diastole observed by electrocardiogram. First, the dia-
meter of the right brachial artery will be searched in a
cross-sectional view and then scanned over a longitudi-
nal section 5 to 10 cm proximal to the right elbow. The
diameter of the brachial artery will be measured from
the anterior to the posterior intima-lumen interface at a
fixed distance. The mean diameter will be calculated
from 4 cardiac cycles. After, a pneumatic tourniquet
placed around the right forearm will be rapidly inflated
to at least 50 mm Hg above the systolic blood pressure
for 5 min. A sudden release of the cuff will induce an
increase in blood flow in the brachial artery located
proximal to the tourniquet. During reactive hyperemia,
there will be an increase in shear stress, causing
endothelium-dependent vasodilatation, mainly due to
endothelial release of nitric oxide [32]. This secondary
dilation enhances and prolongs the reactive hyperaemic
phase. FMD of the brachial artery will be measured
45-60 s after cuff release. The change in diameter
caused by the increased flow will be calculated as the
percentage change relative to the baseline measurement
(FMD%). The dilating brachial artery response due to
shear stress has been shown to have good accuracy and
reproducibility [30,31]. Images will be recorded on DVD
player, for subsequent measurements by two observers
blinded to the study, finally, both measurements will be
averaged.
Biochemical markers
The routine clinical test and those of the endothelial
function and inflammation markers will be processed in
the Proteins, Enzymes and Biochemistry Laboratory-
Universidad of Valle (Cali, Colombia). The oxidative
stress biomarker (F2-isoprostanes) will be measured in
umbilical cord blood using gas chromatography-mass
spectrometry (GC-MS) as previously described [33,34].
Physical activity and health-related physical fitness
Physical activity will be assessed applying the adapted Span-
ish version from the Pregnancy Physical Activity Question-
naire (PPAQ) [35]. The PPAQ measures 1 to 5 physical
activity levels. Moreover, other questionnaires will be admi-
nistered to assess patterns and determinants related to phy-
sical activity such as sedentary behaviour, physical activity
stages, family influence, strategies for behavioural changes,
and environmental factors. In addition, quality of life ques-
tionnaire (SF Community - short-form survey (SF-12™)
(
©1998, 1999 QualityMetric Inc., Lincoln, RI) will be
assessed to record details of current medications, smoking
and alcohol use and dietary patterns [36].
Nutrition
The pregnant women will answer three nutritional ques-
tions: (i) did the participant eat meat the week before,
and if so, how much?; (ii) did the participant eat fried
food the week before, and if so, how often?; and
(iii) how often did the participant eat vegetables and
carbohydrates during the previous week [37].
Study conduct and monitoring
The study will be conducted according to Good Clinical
Practice and to standard operating procedures. The
Human Ethical Committee at the Universidad del Valle
will monitor this clinical trial. The coordinating center
will be composed by physical educators, physicians,
gynaecologists, nurses, physical therapists, clinical epide-
miologists, and bacteriologists. Preliminary monitoring
reports will be submitted to the experts, focusing on
patient intake, adherence to protocol, baseline compar-
ability of treatment groups, completeness of data retrie-
val, and adverse events. All adverse events will also be
reported to the Ethics Committee of the Universidad del
Valle. To standardize study procedures, an operations
manual has been written and comprehensive training
sessions will be held prior to the initiation of the trial.
In addition, there will be weekly conference calls
between the sites, the coordinating center, and the
research chief in order to review procedures and address
problems. To ensure the uniformity and quality of the
interventions at each site, experts in exercise physiology
will train all the therapists prior to the trial initiation
and consult with them on an ongoing basis. The coordi-
nating center will supervise the procedures to ensure
t h eq u a l i t ya n di n t e g r i t yo ft h ed a t a .T h e s ep r o c e s s e s
that include inspections of the data forms as they are
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computer data files will be performed in order to iden-
tify out of range values and missing data forms.
Ethical aspects
The clinical trial will be conducted according to the Hel-
sinki’s Declaration, the Good Clinical Practice Guidelines
and the Colombian legislation (Resolution 8430/93 of the
Ministry of Health). Each participant will provide a writ-
ten informed consent in a form designed for such pur-
pose. The information generated by the study will be
confidential and strictly limited to the purposes stipu-
lated in the protocol. The patient may refuse to continue
participating in the study at any moment after providing
consent. The study has been approved by both the Uni-
versidad of Valle and the Red de Salud Ladera Ethics
committees. All assessments will be performed by trained
staff. The blood samples will be collected in aseptic con-
ditions by an expert bacteriologist. Design and methods
of this RCT are in accordance with the recently published
CONSORT guidelines for trials of nonpharmacological
interventions (http://www.consort-statement.org) [38].
Discussion
At the moment, most of efforts to prevent non-
transmissible chronic diseases at population level have
been centered in promoting healthy behaviors like physical
activity, ingestion of fruits and vegetables, and promoting
the reduction of tobacco and alcohol consumption in the
adult population. Nonetheless, these public health policies
to reduce the burden of non-transmissible chronic dis-
eases have been largely inefficient. In the last years, many
studies have indicated the relation between metabolic
alterations and fetal growth with the development of non-
transmissible chronic diseases in the adulthood. More
recently, it has been proposed that maternal and placental
factors such as endothelial function and oxidative stress
are the precursory mechanisms of fetal metabolic altera-
tions and the posterior development of non-transmissible
chronic diseases. Also, it has been suggested that supple-
mentation with micronutrients and regular physical exer-
cise [39,40] during the gestation can regulate these
maternal and placental factors. For the reasons just men-
tioned, it is necessary to clarify if oxidative stress and
endothelial dysfunction are related to fetal metabolic
alterations and if the supplementation during the gestation
with micronutrients and/or the regular physical exercise
can regulate them, which would be an early and novel
alternative to fortify the prevention of non-transmissible
chronic diseases in the population.
Study timeline
The study will last 36 months. Figure 2.
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